Kyobo 8 Special Purpose Acquisition Company (307280) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyobo 8 Special Purpose Acquisition Company (307280) has a cash flow conversion efficiency ratio of 0.063x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.66 Billion ≈ $1.80 Million USD) by net assets (₩41.96 Billion ≈ $28.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 307280 net asset quality index to measure how much of total assets are equity-financed.
Kyobo 8 Special Purpose Acquisition Company - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Kyobo 8 Special Purpose Acquisition Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Kyobo 8 Special Purpose Acquisition Comp (307280) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Kyobo 8 Special Purpose Acquisition Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyobo 8 Special Purpose Acquisition Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Econframe Bhd
KLSE:0227
|
0.041x |
|
Perdana Gapura Prima Tbk
JK:GPRA
|
-0.009x |
|
Eupe Corporation Bhd
KLSE:6815
|
0.111x |
|
Renta Corporacion Real Estate SA
MC:REN
|
0.248x |
|
A2Z Infra Engineering Limited
NSE:A2ZINFRA
|
-0.172x |
|
Reservoir Link Energy Bhd
KLSE:0219
|
0.075x |
|
Environmental Group Ltd (the)
AU:EGL
|
-0.067x |
|
THE INX DIGITAL CO.INC.
F:FN4
|
N/A |
Annual Cash Flow Conversion Efficiency for Kyobo 8 Special Purpose Acquisition Company (2022–2025)
The table below shows the annual cash flow conversion efficiency of Kyobo 8 Special Purpose Acquisition Company from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Kyobo 8 Special Purpose Acquisition Comp (307280) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩42.62 Billion ≈ $28.89 Million |
₩8.48 Billion ≈ $5.75 Million |
0.199x | -16.18% |
| 2024-12-31 | ₩37.27 Billion ≈ $25.26 Million |
₩8.85 Billion ≈ $6.00 Million |
0.237x | +60.22% |
| 2023-12-31 | ₩32.62 Billion ≈ $22.11 Million |
₩4.84 Billion ≈ $3.28 Million |
0.148x | -31.24% |
| 2022-12-31 | ₩26.83 Billion ≈ $18.18 Million |
₩5.78 Billion ≈ $3.92 Million |
0.216x | -- |
About Kyobo 8 Special Purpose Acquisition Company
Wonbiogen Co., Ltd. manufactures and sells wound dressings in South Korea, rest of Asia, Europe, and internationally. It operates through Wound Dressing and Daily Necessities divisions. The company offers polyurethane foam and hydrocolloid dressings; cosmetics; other dressings; and daily necessities. It also provides medical, organic, and inorganic materials; and laundry detergents. Wonbiogen Co.… Read more